Neoplasm

News

Related Video News

No related video news stories found.

Organic Broadcast Project

Related Videos

No related videos found.

Daiichi Sankyo Initiates Largest Single, Double-Blind, Randomized, Phase III Trial For Treatment And Prevention Of ...

Published February 4, 2010, 6:54 am, PharmaceuticalOnline

Daiichi Sankyo Company, Limited (TSE: 4568), announced today that it has initiated a new large-scale pivotal Phase III trial for edoxaban, its investigational oral Factor Xa inhibitor. This new study, called HOKUSAI (pronounced hoe·koo·sigh) VTE, is evaluating the safety and efficacy of edoxaban in reducing recurrent venous thromboembolic (VTE) complications in patients with deep vein thrombosis ...

Discover News | Full Story


Daiichi Sankyo Initiates Largest Single, Double-Blind, Randomized, Phase III Trial For Treatment Of Recurrent Venous ...

Published February 4, 2010, 5:51 am, Medical News Today

Daiichi Sankyo Company, Limited (TSE: 4568), announced that it has initiated a new large-scale pivotal Phase III trial for edoxaban, its investigational oral Factor Xa inhibitor. This new study, called HOKUSAI (pronounced hoe·koo·sigh) VTE, is evaluating the safety and efficacy of edoxaban in reducing recurrent venous thromboembolic (VTE) complications in patients with deep vein thrombosis ...

Discover News | Full Story


Daiichi Sankyo Initiates Largest Single, Double-Blind, Randomized, Phase III Trial for Treatment and Prevention of ...

Published February 3, 2010, 8:07 am, redOrbit

TOKYO and EDISON, N.J., Feb. 3 /PRNewswire/ -- Daiichi Sankyo Company, Limited (TSE: 4568), announced today that it has initiated a new large-scale pivotal Phase III trial for edoxaban, its investigational oral Factor Xa inhibitor.

Discover News | Full Story


Daiichi Sankyo Initiates Largest Single, Double-Blind, Randomized, Phase III Trial for Treatment and Prevention of ...

Published February 3, 2010, 5:00 am, PR Newswire via Yahoo! Finance

Daiichi Sankyo Company, Limited , announced today that it has initiated a new large-scale pivotal Phase III trial for edoxaban, its investigational oral Factor Xa inhibitor. This new study, called HOKUSAI VTE, is evaluating the safety and efficacy of edoxaban in reducing recurrent venous thromboembolic complications in patients with deep vein thrombosis and/or pulmonary embolism .

Discover News | Full Story


Press Release

Published February 3, 2010, 4:25 am, PharmiWeb

TOKYO, Japan and EDISON, New Jersey, February 3 /PRNewswire/ -- Daiichi Sankyo Company, Limited (TSE: 4568), announced today that it hasinitiated a new large-scale pivotal Phase III trial for edoxaban, itsinvestigational oral Factor Xa inhibitor.

Discover News | Full Story



News Directory

Get started fast by using a pre-defined news directory category

Breaking News
and Top Stories
Business
Earnings, Economy, Personal Finance, and Stock Markets
Entertainment
Books, Celebrity, Fashion, Movies, Music, Television, and Theatre
Health
Aging, Diseases, Medical Conditions, Medications, Sexual Health, and Weight Loss
Politics
Congress, Supreme Court, and White House
Science
Animals, Astronomy, Biotechnology, Space, and Weather
Sports
Baseball, Basketball, Boxing, Football, Golf, Hockey, Motor Sports, Soccer, and Tennis
Technology
Communications, Hardware, Internet, Personal Technology, and Software
United States
and Crimes and Trials
World
Africa, Antartica, Asia, Australia, Canada, Europe, Latin America, and Middle East


© Copyright 2005-2006 News Meme, All Rights Reserved | More News | Link Index | OSWD Design

Powered by Odin Assemble 2.5a